Dehydration Dehydration is another potential side effect of semaglutide that could impact your energy levels
Willing to maintain food tracking, regular weigh-ins, and structured routines indefinitely No significant metabolic dysfunction
These findings suggest that lower doses can still be effective, especially when paired with lifestyle changes like diet and exercise
Semaglutide, which is administered via injection, is typically clear and colourless

Study Snapshot Study Type PM&R-focused narrative review of the medical cannabis literature (not a systematic review or meta-analysis) Clinical Focus Non-pain indications of medical cannabis in physical medicine and rehabilitation Conditions Reviewed Spasticity, neurologic and seizure disorders, sleep disturbances, and chemotherapy-induced nausea and vomiting (CINV) Mechanism Discussed Endocannabinoid system signaling through CB1- and CB2-receptor-mediated pathways affecting neuromodulation, inflammation, and homeostasis Reported Benefits Patient-reported spasticity improvement in multiple sclerosis, seizure reduction in treatment-resistant pediatric epileptic syndromes, antiemetic effects in refractory CINV, and appetite stimulation in cachectic states Sleep Findings Subjective sleep quality improvements reported, but objective sleep architecture changes were inconsistent across studies Functional Outcome Evidence The authors describe limited evidence for meaningful improvement in functional outcomes and quality of life, the core PM&R endpoints Rehabilitation Risks Noted Dose-dependent cognitive impairment, sedation, impaired motor learning, and increased fall risk Evidence Gaps Lack of standardized dosing, variable THC:CBD formulations, inconsistent product labeling, and few high-quality randomized controlled trials measuring long-term functional outcomes Regulatory Context Discrepancies between federal and state cannabis law described as a continued barrier to clinical implementation and research Journal Archives of Internal Medicine Research Published July 2026 PMID 42524265 DOI 10.26502/aimr.0246 Clinical Bottom Line A PM&R-focused narrative review finds modest, patient-reported symptom benefits for spasticity, seizures, chemotherapy-induced nausea, and appetite, but concludes that evidence for functional outcome improvement remains limited and that cannabis carries rehabilitation-specific risks that require careful patient selection and monitoring

Monitor blood glucose as advised